Novartis look to have a major new treatment for heart disease on its hands, in the shape of canakinumab, a drug which has produced exceptional results in a new phase 3 trial.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
